These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

878 related articles for article (PubMed ID: 24577402)

  • 1. Drugging the p53 pathway: understanding the route to clinical efficacy.
    Khoo KH; Verma CS; Lane DP
    Nat Rev Drug Discov; 2014 Mar; 13(3):217-36. PubMed ID: 24577402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Awakening guardian angels: drugging the p53 pathway.
    Brown CJ; Lain S; Verma CS; Fersht AR; Lane DP
    Nat Rev Cancer; 2009 Dec; 9(12):862-73. PubMed ID: 19935675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting protein interactions of p53 for therapeutic intervention: success in a frustrated landscape.
    Blundell TL; Bolanos-Garcia VM
    Cell Cycle; 2009 Nov; 8(22):3631-2. PubMed ID: 19875920
    [No Abstract]   [Full Text] [Related]  

  • 4. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics.
    Zheleva DI; Lane DP; Fischer PM
    Mini Rev Med Chem; 2003 May; 3(3):257-70. PubMed ID: 12698949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
    Dickens MP; Fitzgerald R; Fischer PM
    Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
    Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness.
    Moreira J; Almeida J; Saraiva L; Cidade H; Pinto M
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34205272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p53 pathway: targets for the development of novel cancer therapeutics.
    Wang S; El-Deiry WS
    Cancer Treat Res; 2004; 119():175-87. PubMed ID: 15164878
    [No Abstract]   [Full Text] [Related]  

  • 9. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
    Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA
    J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A; Mohammed AA; Shaik TB
    Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of MDM2 and MDMX: a structural perspective.
    Riedinger C; McDonnell JM
    Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational approaches targeting the p53 pathway for anti-cancer therapy.
    Essmann F; Schulze-Osthoff K
    Br J Pharmacol; 2012 Jan; 165(2):328-44. PubMed ID: 21718309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological reactivation of p53 as a strategy to treat cancer.
    Zawacka-Pankau J; Selivanova G
    J Intern Med; 2015 Feb; 277(2):248-259. PubMed ID: 25495071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibitors of the p53-MDM2 interaction.
    Vu BT; Vassilev L
    Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule compounds targeting the p53 pathway: are we finally making progress?
    Yu X; Narayanan S; Vazquez A; Carpizo DR
    Apoptosis; 2014 Jul; 19(7):1055-68. PubMed ID: 24756955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide activators of the p53 tumor suppressor.
    Zhan C; Lu W
    Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
    Chène P
    Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug discovery and mutant p53.
    Maslon MM; Hupp TR
    Trends Cell Biol; 2010 Sep; 20(9):542-55. PubMed ID: 20656489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.